[
  {
      "patent_id": "US-8822456-B2",
      "title": "Method of treating neurodegenerative disorders with Biguanides",
      "assignee": "NeuroPharma Inc.",
      "abstract": "A method for treating Alzheimer's disease comprising administering a therapeutically effective amount of metformin in combination with a cholinesterase inhibitor to reduce beta-amyloid plaque formation.",
      "claims": "1. A method of treating Alzheimer's disease comprising administering metformin. 2. The method wherein the dose is 500mg daily. 3. The method wherein metformin is combined with donepezil.",
      "status": "Active",
      "filing_date": "2015-06-12",
      "expiry_date": "2035-06-12",
      "cpc_codes": ["A61K31/155", "A61P25/28"],
      "molecule": "Metformin",
      "indication": "Alzheimer's Disease"
  },
  {
      "patent_id": "US-6011001-A",
      "title": "Immediate release Metformin Hydrochloride tablets",
      "assignee": "GenericCo Ltd.",
      "abstract": "A pharmaceutical composition comprising metformin hydrochloride and a hydrophilic polymer for immediate release formulations with improved bioavailability.",
      "claims": "1. An immediate release tablet comprising 500mg metformin HCl and povidone.",
      "status": "Expired",
      "filing_date": "1998-01-01",
      "expiry_date": "2018-01-01",
      "cpc_codes": ["A61K9/20"],
      "molecule": "Metformin",
      "indication": "Type 2 Diabetes"
  },
  {
      "patent_id": "US-20230055123-A1",
      "title": "Transdermal delivery system for Metformin",
      "assignee": "DermaDeliver S.A.",
      "abstract": "A patch formulation for sustained delivery of biguanides through the skin to minimize gastrointestinal side effects and improve patient compliance.",
      "claims": "1. A transdermal patch comprising a backing layer and a drug-in-adhesive matrix containing metformin. 2. The patch of claim 1 wherein release is over 24 hours.",
      "status": "Pending",
      "filing_date": "2023-02-15",
      "expiry_date": "2043-02-15",
      "cpc_codes": ["A61K9/70"],
      "molecule": "Metformin",
      "indication": "Type 2 Diabetes"
  },
  {
      "patent_id": "US-10234567-B2",
      "title": "Metformin extended release with reduced GI side effects",
      "assignee": "BioFormulations Corp.",
      "abstract": "An extended release formulation of metformin using HPMC matrix technology to provide 12-hour sustained release with improved gastrointestinal tolerability.",
      "claims": "1. An extended release tablet containing metformin and HPMC. 2. The tablet providing plasma concentration over 12 hours.",
      "status": "Active",
      "filing_date": "2019-08-20",
      "expiry_date": "2039-08-20",
      "cpc_codes": ["A61K9/22", "A61K31/155"],
      "molecule": "Metformin",
      "indication": "Type 2 Diabetes"
  },
  {
      "patent_id": "US-11345678-B1",
      "title": "Combination therapy of Metformin and GLP-1 agonist",
      "assignee": "DiabetesCure Pharma",
      "abstract": "A fixed-dose combination of metformin and semaglutide for improved glycemic control in type 2 diabetes patients.",
      "claims": "1. A pharmaceutical composition comprising metformin and semaglutide. 2. A method of treating diabetes using the composition of claim 1.",
      "status": "Active",
      "filing_date": "2021-03-10",
      "expiry_date": "2041-03-10",
      "cpc_codes": ["A61K31/155", "A61K38/26"],
      "molecule": "Metformin + Semaglutide",
      "indication": "Type 2 Diabetes"
  },
  {
      "patent_id": "US-9876543-B2",
      "title": "Use of Metformin in treating polycystic ovary syndrome",
      "assignee": "WomensHealth Inc.",
      "abstract": "A method of treating PCOS symptoms including insulin resistance, irregular menstruation, and hyperandrogenism using metformin.",
      "claims": "1. A method of treating PCOS comprising administering 1500-2000mg metformin daily. 2. The method of claim 1 for improving ovulation.",
      "status": "Active",
      "filing_date": "2016-05-22",
      "expiry_date": "2036-05-22",
      "cpc_codes": ["A61K31/155", "A61P15/00"],
      "molecule": "Metformin",
      "indication": "PCOS"
  },
  {
      "patent_id": "US-8765432-A1",
      "title": "Metformin for cancer prevention and treatment",
      "assignee": "OncoPharma Ltd.",
      "abstract": "Use of metformin in combination with standard chemotherapy for treating various cancers including breast, colon, and pancreatic cancer through AMPK activation.",
      "claims": "1. A method of treating cancer comprising metformin and a chemotherapeutic agent. 2. The method of claim 1 for breast cancer treatment.",
      "status": "Pending",
      "filing_date": "2022-11-30",
      "expiry_date": "2042-11-30",
      "cpc_codes": ["A61K31/155", "A61P35/00"],
      "molecule": "Metformin",
      "indication": "Cancer"
  },
  {
      "patent_id": "US-7654321-B2",
      "title": "Anti-aging effects of Metformin",
      "assignee": "LongevityBio Corp.",
      "abstract": "Methods of extending lifespan and reducing age-related diseases using metformin to activate AMPK and inhibit mTOR signaling pathways.",
      "claims": "1. A method of promoting healthy aging comprising administering low-dose metformin. 2. Use of metformin for reducing cellular senescence.",
      "status": "Active",
      "filing_date": "2017-09-15",
      "expiry_date": "2037-09-15",
      "cpc_codes": ["A61K31/155", "A61P43/00"],
      "molecule": "Metformin",
      "indication": "Anti-aging"
  },
  {
      "patent_id": "US-5432109-A",
      "title": "Metformin liquid formulation for pediatric use",
      "assignee": "PediaRx Pharma",
      "abstract": "A stable oral liquid formulation of metformin with cherry flavoring for pediatric type 2 diabetes patients.",
      "claims": "1. An oral liquid comprising metformin 100mg/5mL with cherry flavor. 2. A method of treating pediatric diabetes.",
      "status": "Expired",
      "filing_date": "2000-04-10",
      "expiry_date": "2020-04-10",
      "cpc_codes": ["A61K9/08", "A61K31/155"],
      "molecule": "Metformin",
      "indication": "Pediatric Diabetes"
  },
  {
      "patent_id": "US-12456789-A1",
      "title": "Metformin nanoparticle formulation for enhanced CNS penetration",
      "assignee": "NanoBrain Therapeutics",
      "abstract": "Nanoparticle-encapsulated metformin designed to cross the blood-brain barrier for treating neurodegenerative diseases including Parkinson's and Alzheimer's.",
      "claims": "1. A nanoparticle formulation comprising metformin coated with transferrin-conjugated polymers. 2. A method of treating Parkinson's disease.",
      "status": "Pending",
      "filing_date": "2024-01-20",
      "expiry_date": "2044-01-20",
      "cpc_codes": ["A61K9/51", "A61K31/155", "A61P25/16"],
      "molecule": "Metformin",
      "indication": "Parkinson's Disease"
  }
]